Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 1/20 | 0.43 |
| ▸ | TRPM8 | Q7Z2W7 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | SCD | O00767 | 1/20 | 0.37 |
| ▸ | GPR142 | Q7Z601 | 1/20 | 0.37 |
| ▸ | PLAUR | Q03405 | 1/20 | 0.36 |
| ▸ | SCD5 | Q86SK9 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | TACR3 | P29371 | 1/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.35 |
| ▸ | MTOR | P42345 | 1/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.34 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.34 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.34 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9901781 | 0.85 | MKNK1 (0.42) | RIPK1TRPM8SMN1; SMN2SCD5 | |
| SCHEMBL9902355 | 0.80 | GRM2 (0.39) | RIPK1KDM4ESMN1; SMN2SCDSCD5 | |
| SCHEMBL9903679 | 0.80 | GRM2 (0.39) | RIPK1KDM4ESMN1; SMN2SCDSCD5 | |
| SCHEMBL9903640 | 0.78 | RIPK1 (0.38) | RIPK1 | |
| SCHEMBL9903564 | 0.72 | HTR7 (0.37) | RIPK1KDM4ESMN1; SMN2PDE4B | |
| SCHEMBL9902640 | 0.69 | BRD4 (0.40) | SCD5 | |
| SCHEMBL9902312 | 0.67 | RIPK1 (0.33) | RIPK1 | |
| SCHEMBL3283691 | 0.66 | MAPK1 (0.43) | RIPK1PDE4B | |
| SCHEMBL12465745 | 0.64 | HSD17B10 (0.51) | KDM4ESMN1; SMN2RAB9ANR4A1NR4A2 | |
| SCHEMBL27791860 | 0.62 | MAPT (0.43) | TRPM8KDM4ESMN1; SMN2RAB9APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8916549-B2 | Thienooxazepine derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-12-23 | — | — | US | disclosed |
| EP-2463290-B1 | THIENOOXAZEPINE DERIVATIVE | TAKEDA PHARMACEUTICAL (JP) | 2014-03-05 | — | — | EP | disclosed |
| US-20120196848-A1 | THIENOOXAZEPINE DERIVATIVE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-08-02 | — | — | US | disclosed |
| EP-2463290-A1 | THIENOOXAZEPINE DERIVATIVE | Takeda Pharmaceutical Company Limited (JP) | 2012-06-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120196848-A1 | THIENOOXAZEPINE DERIVATIVE | HTR2C, HTR2B, HTR2A | RIPK1 2833/4885TRPM8 95/4885KDM4E 2389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.